Their technology uses high quality fluorescent G-protein-coupled receptor ligands for molecular pharmacology and cell imaging. eg technology is working with the team at CellAura to develop their perfusion system into a commercially viable instrument.
To date, eg has carried out several phases of work to define the instrument specification, provide conceptual CAD of the instrument and, most recently, to design and build a breadboard prototype of the fluid handling system to test and de-risk the proposed architecture and fluid-handling software.
Dai Hayward, CellAura's Chief Executive, said "Working with eg technology has been a pleasure. Their project team has listened patiently to discern our real requirements and then shaped our thinking to ensure that these needs have been met in a thoroughly professional manner."
CellAura are aiming to trial beta systems with selected partners before the end of 2012, with the first commercial units available early in 2013.